Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

October 1, 2020

Study Completion Date

October 20, 2020

Conditions
Covid19SARS-CoV-2 PNEUMONIACOVID-19
Interventions
DRUG

EXO 1 inhalation

Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.

DRUG

EXO 2 inhalation

Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.

DRUG

Placebo inhalation

Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).

Trial Locations (1)

443095

Medical Centre Dinasty, Samara

All Listed Sponsors
collaborator

Samara State Medical University

OTHER

collaborator

Samara Regional Clinical Hospital V.D. Seredavin

OTHER

lead

"State-Financed Health Facility Samara Regional Medical Center Dinasty"

OTHER

NCT04491240 - Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia. | Biotech Hunter | Biotech Hunter